articleURL: 0
10.1021/acs.jmedchem.9b00446
{"compound": "", "ic50_mc": "( fda ) against alk-positive nsclcs . novel type-i1/2 and type-ii alk inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported . moreover", "kd_mc": "alk ) has been validated to play important roles in various cancers , especially anaplastic large cell lymphoma ( alcl", "ic50_ce": "alk ) has been validated to play important roles in various cancers , especially anaplastic large cell lymphoma ( alcl ) , nonsmall cell lung cancer ( nsclc ) , and neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib , brigatinib , and lorlatinib , have been approved by the u . s . food and drug administration ( fda ) against alk-positive nsclcs . novel type-i1/2 and type-ii alk inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported . moreover , the “proteolysis targeting chimera” ( protac ) technique has been successfully applied in developing alk degraders", "selectivity_ce": "<unk> . in this paragraph , can you find out the result of selectivity_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] drug discovery targeting anaplastic lymphoma kinase ( alk ) as a receptor tyrosine kinase of insulin receptor ( ir ) subfamily , anaplastic lymphoma kinase ( alk ) has been validated to play important roles in various cancers , especially anaplastic large cell lymphoma ( alcl ) , nonsmall cell lung cancer ( nsclc ) , and neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib , brigatinib , and lorlatinib , have been approved by the u . s . food and drug administration ( fda ) against alk-positive nsclcs . novel", "herg_ce": "( fda ) against alk-positive nsclcs . novel type-i1/2 and type-ii alk inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported . moreover , the “proteolysis targeting chimera” ( protac ) technique has been successfully applied in developing alk degraders", "ed50_an": "nsclc ) , and neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib , brigatinib , and lorlatinib , have been approved by the u . s . food and drug administration ( fda ) against alk-positive nsclcs . novel type-i1/2 and type-ii alk inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported . moreover , the “proteolysis targeting chimera” ( protac ) technique has been successfully applied in developing alk degraders , which opened a new avenue for targeted alk therapies . this review provides an overview of the physiological and biological functions of alk , the discovery and development of drugs targeting alk by focusing on their chemotypes , activity , selectivity , and resistance as well as potential therapeutic strategies to overcome drug resistance . . [SEP]", "t_half_an": "<unk> . in this paragraph , can you find out the result of t_half_an ? [SEP] [CLS] what is the compound in this paper ? [SEP] drug discovery targeting anaplastic lymphoma kinase ( alk ) as a receptor tyrosine kinase of insulin receptor ( ir ) subfamily , anaplastic lymphoma kinase ( alk ) has been validated to play important roles in various cancers , especially anaplastic large cell lymphoma ( alcl ) , nonsmall cell lung cancer ( nsclc ) , and neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib , brigatinib , and lorlatinib , have been approved by the u . s", "bioavailability_an": "neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib , brigatinib , and lorlatinib , have been approved by the u . s . food and drug administration ( fda ) against alk-positive nsclcs . novel type-i1/2 and type-ii alk inhibitors with improved kinase selectivity and enhanced capability to combat drug resistance have also been reported", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] drug discovery targeting anaplastic lymphoma kinase ( alk ) as a receptor tyrosine kinase of insulin receptor ( ir ) subfamily , anaplastic lymphoma kinase ( alk ) has been validated to play important roles in various cancers , especially anaplastic large cell lymphoma ( alcl ) , nonsmall cell lung cancer ( nsclc ) , and neuroblastomas . currently , five small-molecule inhibitors of alk , including crizotinib , ceritinib , alectinib"}


{"id": 0, "paper_title": "Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["Xiaotian Kong", "Peichen Pan", "Huiyong Sun", "Hongguang Xia", "Xuwen Wang", "Youyong Li", "Tingjun Hou"], "paper_year": 2019, "paper_institution": "Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China", "paper_cited": 22, "doi": "10.1021/acs.jmedchem.9b00446", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b00446/20191219/images/large/jm9b00446_0028.jpeg", "compound_count": 65, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 1
10.1021/acs.jmedchem.1c00270
{"compound": "1 7", "ic50_mc": "1", "ic50_ce": "1 7 , 2 2 ,", "ed50_an": "9 ± 0 . 1 3 nm ) and are >3 times more potent than alectinib ( 3: ic50", "bioavailability_an": "7 5 . 8 2"}


{"id": 1, "paper_title": "Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["Shaowen Xie", "Yuan Sun", "Yulin Liu", "Xinnan Li", "Xinuo Li", "Wenyi Zhong", "Feiyan Zhan", "Jingjie Zhu", "Hong Yao", "Dong-Hua Yang", "Zhe-Sheng Chen", "Jinyi Xu", "Shengtao Xu"], "paper_year": 2021, "paper_institution": "State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, P. R. China", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00270", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00270/20210629/images/large/jm1c00270_0024.jpeg", "compound_count": 55, "compound_name": "17", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 17.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 75.82}, "clinical_statistics": {}}
articleURL: 2
10.1021/jm500261q
{"compound": "8k", "ic50_mc": "1 . 0", "kd_mc": "3", "selectivity_mc": "610-fold", "selectivity_ce": "1 0", "ed50_an": "1 phospho-alk ic50 values in nih-3t3 cell lines engineered with mutations reported from the clinic have been previously described . ( 2 4 ) the mutant cell ic50 data for compound 1 ranged from 1 6 5 to 3 0 3 9 nm , which represented a 2–38-fold shift relative to the wt potency ( palk cell ic50 = 8 0 nm ) in the same engineered line .", "bioavailability_an": "1 0 0 %", "compound_drug": "pf-06463922"}


{"id": 2, "paper_title": "Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations", "paper_author": ["Ted W. Johnson", "Paul F. Richardson", "Simon Bailey", "Alexei Brooun", "Benjamin J. Burke", "Michael R. Collins", "J. Jean Cui", "Judith G. Deal", "Ya-Li Deng", "Dac Dinh", "Lars D. Engstrom", "Mingying He", "Jacqui Hoffman", "Robert L. Hoffman", "Qinhua Huang", "Robert S. Kania", "John C. Kath", "Hieu Lam", "Justine L. Lam", "Phuong T. Le", "Laura Lingardo", "Wei Liu", "Michele McTigue", "Cynthia L. Palmer", "Neal W. Sach", "Tod Smeal", "Graham L. Smith", "Albert E. Stewart", "Sergei Timofeevski", "Huichun Zhu", "Jinjiang Zhu", "Helen Y. Zou", "Martin P. Edwards"], "paper_year": 2014, "paper_institution": "La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States", "paper_cited": 265, "doi": "10.1021/jm500261q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-11/jm500261q/production/images/large/jm-2014-00261q_0018.jpeg", "compound_count": 102, "compound_name": "8k", "compound_name_drug": "PF-06463922", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 3.0, "IC50": 1.0, "selectivity": 610}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 100.0}, "clinical_statistics": {"p1_company_num": 11, "p1_stat_company_num": [0, 2, 0, 0, 0, 0, 9, 0, 0], "p1_company": [[], ["OHSU Knight Cancer Institute", "Children's Hospital of Philadelphia"], [], [], [], [], ["National Cancer Center", "University of Milano Bicocca", "Pfizer", "NRG Oncology", "Massachusetts General Hospital", "Grenoble - CHU", "Erasmus MC, Rotterdam, Netherlands", "Lyon - URCOT", "The Netherlands Cancer Institute"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {"Pfizer": 0.0}, "p2_company_num": 9, "p2_stat_company_num": [0, 7, 0, 1, 0, 0, 1, 0, 0], "p2_company": [[], ["National Cancer Center", "University of Milano Bicocca", "Massachusetts General Hospital", "Grenoble - CHU", "Erasmus MC, Rotterdam, Netherlands", "Lyon - URCOT", "The Netherlands Cancer Institute"], [], ["NRG Oncology"], [], [], ["Pfizer"], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {}, "p3_company_num": 1, "p3_stat_company_num": [0, 0, 0, 1, 0, 0, 0, 0, 0], "p3_company": [[], [], [], ["Pfizer"], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 3
10.1021/acs.jmedchem.6b00106
{"compound": "5a", "ic50_mc": "7 . 8 4", "kd_mc": "1 . 9 2 å", "selectivity_mc": "32-fold", "herg_ce": "1 0"}


{"id": 3, "paper_title": "Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["Chih-Hsiang Tu", "Wen-Hsing Lin", "Yi-Hui Peng", "Tsu Hsu", "Jian-Sung Wu", "Chun-Yu Chang", "Cheng-Tai Lu", "Ping-Chiang Lyu", "Chuan Shih", "Weir-Torn Jiaang", "Su-Ying Wu"], "paper_year": 2016, "paper_institution": "Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC", "paper_cited": 18, "doi": "10.1021/acs.jmedchem.6b00106", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.6b00106/20160422/images/large/jm-2016-00106d_0011.jpeg", "compound_count": 15, "compound_name": "5a", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.92, "IC50": 7.84, "selectivity": 32}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 4
10.1021/acs.jmedchem.7b01655
{"compound": "abcb1", "ic50_ce": "5 0", "ed50_an": "9 ) as control compounds to complement the degraders 9 and 1 1 , we designed the analogs 1 0 and 1 2 with des-carbonyl pomalidomide groups that exhibit substantially weakened binding to cereblon , as confirmed by a biochemical cereblon binding assay ( figures 1a and s1 ) . using an alk activity assay , we validated that the degraders and their des-carbonyl counterparts are still able to bind alk , with ic50 values comparable to their parental kinase inhibitors ( figure 1b , table s1 ) .", "t_half_an": "1", "compound_drug": "ldk378"}


{"id": 4, "paper_title": "Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["Chelsea E. Powell", "Yang Gao", "Li Tan", "Katherine A. Donovan", "Radosław P. Nowak", "Amanda Loehr", "Magda Bahcall", "Eric S. Fischer", "Pasi A. Jänne", "Rani E. George", "Nathanael S. Gray"], "paper_year": 2018, "paper_institution": "Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States", "paper_cited": 73, "doi": "10.1021/acs.jmedchem.7b01655", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-9/acs.jmedchem.7b01655/20180504/images/large/jm-2017-01655v_0007.jpeg", "compound_count": 12, "compound_name": "abcb1", "compound_name_drug": "abcb1", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 50.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.009, "AUC": "", "solubility": "", "t_half": 1.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 5
10.1021/acs.jmedchem.6b00064
{"compound": "2", "ic50_mc": "1 2"}


{"id": 5, "paper_title": "Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor", "paper_author": ["Maria Menichincheri", "Elena Ardini", "Paola Magnaghi", "Nilla Avanzi", "Patrizia Banfi", "Roberto Bossi", "Laura Buffa", "Giulia Canevari", "Lucio Ceriani", "Maristella Colombo", "Luca Corti", "Daniele Donati", "Marina Fasolini", "Eduard Felder", "Claudio Fiorelli", "Francesco Fiorentini", "Arturo Galvani", "Antonella Isacchi", "Andrea Lombardi Borgia", "Chiara Marchionni", "Marcella Nesi", "Christian Orrenius", "Achille Panzeri", "Enrico Pesenti", "Luisa Rusconi", "Maria Beatrice Saccardo", "Ermes Vanotti", "Ettore Perrone", "Paolo Orsini"], "paper_year": 2016, "paper_institution": "Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy", "paper_cited": 107, "doi": "10.1021/acs.jmedchem.6b00064", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-7/acs.jmedchem.6b00064/20160414/images/large/jm-2016-000643_0008.jpeg", "compound_count": 34, "compound_name": "2", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 12.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": "μm20"}, "pharm_metrics_vivo": {"ED50": "", "AUC": "μm19.6 ± 1.5", "solubility": "", "t_half": "μm3.59 ± 0.47", "bioavailability": "μm77"}, "clinical_statistics": {}}
articleURL: 6
10.1021/acs.jmedchem.8b01630
{"compound": "1 3", "ic50_mc": "1 . 8", "selectivity_mc": "1", "ic50_ce": "2", "ed50_an": "1 nm ) and moderate kinase selectivity in an enzymatic kinase panel that consisted of 3 9 different kinases ( see supporting information ) . compound 1 is a chiral compound and its absolute configuration was determined as s-form . an r-isomer of compound 1 showed lower alk inhibitory activity with ic50 value of 1 0 0 0 nm .", "compound_drug": "leu1256 formed three ch−π interactions with the imidazole ring , the pyridazine ring in the imidazo[1 , 2-b]pyridazine core , and the 2 , 4-difluorophenyl group , leading to robust stabilization of the l-shaped conformation of the molecule . next , we analyzed the difference of the amino acid sequence in the atp binding pocket between alk and trka to improve selectivity over the trks . four amino acid residues in alk were identified for consideration: ala1200 , his1124"}


{"id": 6, "paper_title": "Discovery of Potent, Selective, and Brain-Penetrant 1H-Pyrazol-5-yl-1H-pyrrolo[2,3-b]pyridines as Anaplastic Lymphoma Kinase (ALK) Inhibitors", "paper_author": ["Makoto Fushimi", "Ikuo Fujimori", "Takeshi Wakabayashi", "Tomoaki Hasui", "Youichi Kawakita", "Keisuke Imamura", "Tomoko Kato", "Morio Murakami", "Tsuyoshi Ishii", "Yorifumi Kikko", "Maki Kasahara", "Atsushi Nakatani", "Yuto Hiura", "Maki Miyamoto", "Kumar Saikatendu", "Hua Zou", "Scott Weston Lane", "J. David Lawson", "Hiroshi Imoto"], "paper_year": 2019, "paper_institution": "Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan", "paper_cited": 5, "doi": "10.1021/acs.jmedchem.8b01630", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-10/acs.jmedchem.8b01630/20190516/images/large/jm-2018-01630m_0020.jpeg", "compound_count": 59, "compound_name": "13", "compound_name_drug": "", "compound_smiles": "[C@H](c1c(F)cc(F)cc1)(Nc1nn2c(ncc2c2[nH]nc(C)c2)cc1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 7
10.1021/jm5005144
{"compound": "1 5", "ic50_mc": "1 5 . 3", "selectivity_mc": "1", "kd_ce": "2", "ed50_an": "6 . 5 and 3 2", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion enzymatic assay meanwhile , to elucidate the necessity of the primary amino group for the high alk potency of compound 1 5 , a large number of 2-amino acetamido fragments bearing diversified substitutions on either the amino group or the alkyl chain or both were investigated . as shown in table 3 , substitution on the primary amino group by forming an azetidine ring led to compound 3 1"}


{"id": 7, "paper_title": "Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases", "paper_author": ["Zilan Song", "Yanhong Yang", "Zhiqing Liu", "Xia Peng", "Junfeng Guo", "Xinying Yang", "Kui Wu", "Jing Ai", "Jian Ding", "Meiyu Geng", "Ao Zhang"], "paper_year": 2014, "paper_institution": "CAS Key Laboratory of Receptor Research, Synthetic Organic & Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai 201203, China", "paper_cited": 33, "doi": "10.1021/jm5005144", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-1/jm5005144/20150106/images/large/jm-2014-005144_0011.jpeg", "compound_count": 48, "compound_name": "15", "compound_name_drug": "", "compound_smiles": "c1c(F)c(Nc2nc(NC3=C[C]4(=[I](C(C[C@@H]5C(=[O][C@@H]5N(C(=O)N5CCCC5)$C)N4)(C)C[C@H](I)C)C=C3)C)ncc2Cl)c(C(=O)NC)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 15.3, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "μm15.3 ± 3.7", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 6.5, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 8
10.1021/acs.jmedchem.6b00487
{"compound": "27b", "ic50_mc": "9 .", "kd_ce": "2", "herg_ce": "1 0", "t_half_an": "1 2", "bioavailability_an": "1 1 %", "compound_drug": "cep-37440"}


{"id": 8, "paper_title": "Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["Gregory R. Ott", "Mangeng Cheng", "Keith S. Learn", "Jason Wagner", "Diane E. Gingrich", "Joseph G. Lisko", "Matthew Curry", "Eugen F. Mesaros", "Arup K. Ghose", "Matthew R. Quail", "Weihua Wan", "Lihui Lu", "Pawel Dobrzanski", "Mark S. Albom", "Thelma S. Angeles", "Kevin Wells-Knecht", "Zeqi Huang", "Lisa D. Aimone", "Elizabeth Bruckheimer", "Nathan Anderson", "Jay Friedman", "Sandra V. Fernandez", "Mark A. Ator", "Bruce A. Ruggeri", "Bruce D. Dorsey"], "paper_year": 2016, "paper_institution": "Teva Branded Pharmaceutical Products R&D, 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States", "paper_cited": 43, "doi": "10.1021/acs.jmedchem.6b00487", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-16/acs.jmedchem.6b00487/20160819/images/large/jm-2016-004872_0023.jpeg", "compound_count": 62, "compound_name": "27b", "compound_name_drug": "", "compound_smiles": "C1CCc2c(C)c(C)ccc2CC1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 9.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": "", "selectivity": "", "hERG": 10.0, "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 12.0, "bioavailability": 11.0}, "clinical_statistics": {}}
articleURL: 9
10.1021/jm2010767
{"compound": "3 2", "ic50_mc": "6", "selectivity_ce": "1", "t_half_an": "3", "bioavailability_an": "5 6 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] in theory , p-ch-anilines would still be capable of bioactivation to quinonemethide imine species; however , the oxidation potential relative to dianilines was expected to be dramatically diminished"}


{"id": 9, "paper_title": "Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-f][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors", "paper_author": ["Eugen F. Mesaros", "Tho V. Thieu", "Gregory J. Wells", "Craig A. Zificsak", "Jason C. Wagner", "Henry J. Breslin", "Rabindranath Tripathy", "James L. Diebold", "Robert J. McHugh", "Ashley T. Wohler", "Matthew R. Quail", "Weihua Wan", "Lihui Lu", "Zeqi Huang", "Mark S. Albom", "Thelma S. Angeles", "Kevin J. Wells-Knecht", "Lisa D. Aimone", "Mangeng Cheng", "Mark A. Ator", "Gregory R. Ott", "Bruce D. Dorsey"], "paper_year": 2011, "paper_institution": "Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States ", "paper_cited": 20, "doi": "10.1021/jm2010767", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm2010767/production/images/large/jm-2011-010767_0013.jpeg", "compound_count": 42, "compound_name": "32", "compound_name_drug": "", "compound_smiles": "c1c(c(ccc1C(CCC)CCC)N)O", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 6.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": 56.0}, "clinical_statistics": {}}
articleURL: 10
10.1021/acs.jmedchem.8b01947
{"compound": "16k", "kd_mc": "0 . 1 9 nm .", "selectivity_mc": "26-fold", "ic50_ce": "5 0 nm", "bioavailability_an": "9 8", "compound_drug": "brd4"}


{"id": 10, "paper_title": "Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity", "paper_author": ["Ellen Watts", "David Heidenreich", "Elizabeth Tucker", "Monika Raab", "Klaus Strebhardt", "Louis Chesler", "Stefan Knapp", "Benjamin Bellenie", "Swen Hoelder"], "paper_year": 2019, "paper_institution": "Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, U.K.", "paper_cited": 22, "doi": "10.1021/acs.jmedchem.8b01947", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01947/20190308/images/large/jm-2018-01947q_0015.jpeg", "compound_count": 84, "compound_name": "16k", "compound_name_drug": "Bromodomain-4", "compound_smiles": "c1c(csc1CN1[C@@H](C(=O)N(c2c1nc(Nc1c(cc(C3CCN(CC3)C)cc1)OCC)nc2)C)CC)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 0.19, "IC50": "", "selectivity": 26}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 50.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 98.0}, "clinical_statistics": {}}
articleURL: 11
10.1021/jm3005866
{"compound": "4 9", "ic50_mc": "1", "kd_ce": "2", "ed50_an": "2 ( table 2 ) indicated that replacement of the ester moiety of 1 4 with an ethyl amide 1 5 afforded an improvement in cellular potency , together with significant enhancement of selectivity against jak2 . a modest impact on src selectivity was noted , without significant change in selectivity against igf1r .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion ester 2 afforded a good starting point in terms of potent enzymatic inhibition of alk . however , significant improvements to cellular potency , off-target kinase selectivity profile , and a dramatic improvement in metabolic stability were required . a brief examination of sar of the methyl ester moiety of 2 ( table 2"}


{"id": 11, "paper_title": "The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer", "paper_author": ["Richard T. Lewis", "Christiane M. Bode", "Deborah M. Choquette", "Michele Potashman", "Karina Romero", "John C. Stellwagen", "Yohannes Teffera", "Earl Moore", "Douglas A. Whittington", "Hao Chen", "Linda F. Epstein", "Renee Emkey", "Paul S. Andrews", "Violeta L. Yu", "Douglas C. Saffran", "Man Xu", "Allison Drew", "Patricia Merkel", "Steven Szilvassy", "Rachael L. Brake"], "paper_year": 2012, "paper_institution": "Amgen Inc., 360 Binney Street, Cambridge Massachusetts 02142, United States", "paper_cited": 30, "doi": "10.1021/jm3005866", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-14/jm3005866/production/images/large/jm-2012-005866_0013.jpeg", "compound_count": 60, "compound_name": "49", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.002, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 12
10.1021/jm201333e
{"compound": "2m", "ic50_mc": "1 . 2 9", "ki_mc": "6 , 9 ( 2 1", "kd_mc": "2", "selectivity_mc": "7", "ic50_ce": "1 0", "ec50_ce": "3 ( 2 2 ) , 4 , 6 , 9 ( 2 1 ) , 1 0", "selectivity_ce": "1 2", "ed50_an": "1 . 2 9 å ( figure 5 ) . these encouraging modeling results added confidence that the proposed macrocycles 2 would show promise as alk inhibitors . subsequent to these modeling experiments , solid state crystal structures of apo and ligand bound structures ( including dap bound ) of alk were reported in the literature and showed similar conformational arrangement of the dap’s three aryl groups . ( 1 3 )", "t_half_an": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results scheme 1 comprehensively outlines the routes used to prepare macrocycles 2a–m . a minimally substituted macrocycle ( 2a ) was prepared to validate the synthetic sequence . 3-bromoaniline ( 3a ) was reacted with 2 , 4 , 5-trichloropyrimidine ( 4"}


{"id": 12, "paper_title": "Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles", "paper_author": ["Henry J. Breslin", "Brandon M. Lane", "Gregory R. Ott", "Arup K. Ghose", "Thelma S. Angeles", "Mark S. Albom", "Mangeng Cheng", "Weihua Wan", "R. Curtis Haltiwanger", "Kevin J. Wells-Knecht", "Bruce D. Dorsey"], "paper_year": 2011, "paper_institution": "Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380-4245, United States", "paper_cited": 28, "doi": "10.1021/jm201333e", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-1/jm201333e/production/images/large/jm-2011-01333e_0008.jpeg", "compound_count": 96, "compound_name": "2m", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 6.0, "Kd": 2.0, "IC50": 1.29, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 10.0, "EC50": 3.0, "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.0012900000000000001, "AUC": "", "solubility": "", "t_half": 1.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 13
10.1021/jm200758k
{"compound": "3 0", "ki_mc": "2 0 0 nm", "ic50_ce": "6 0", "ed50_an": "7 ( n-methyl piperazinylphenyl ) and 1 8 ( methoxyethyl-tetrahydrobenzazepine ) proved more active; ir activity for these examples roughly paralleled alk activity .", "t_half_an": "3", "bioavailability_an": "8 3 %", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion having demonstrated clear sar with the aniline fragment , we turned our attention toward the derivatization of the c7 aryl moiety ( table 2 ) using the 4- ( n-methylpiperazinyl ) aniline at the c2 position . following trends associated with improving both potency and selectivity on the diaminopyrimidine core , we focused our efforts on the 2-position of the pendant aryl ring with emphasis on groups containing hydrogen bond acceptors . the introduction of the 2-methoxy group ( 1 9 ) provided a >2-fold boost to alk enzymatic activity as compared to 1 7 as well as modest separation ( 6-fold ) from ir . interestingly , the introduction of the 2-carboxamide ( 2 0"}


{"id": 13, "paper_title": "2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity", "paper_author": ["Gregory R. Ott", "Gregory J. Wells", "Tho V. Thieu", "Matthew R. Quail", "Joseph G. Lisko", "Eugen F. Mesaros", "Diane E. Gingrich", "Arup K. Ghose", "Weihua Wan", "Lihui Lu", "Mangeng Cheng", "Mark S. Albom", "Thelma S. Angeles", "Zeqi Huang", "Lisa D. Aimone", "Mark A. Ator", "Bruce A. Ruggeri", "Bruce D. Dorsey"], "paper_year": 2011, "paper_institution": "Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States", "paper_cited": 33, "doi": "10.1021/jm200758k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200758k/production/images/large/jm-2011-00758k_0007.jpeg", "compound_count": 38, "compound_name": "30", "compound_name_drug": "", "compound_smiles": "c1c(c(ccc1C)N)O", "medicinal_chemistry_metrics": {"Ki": 200.0, "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 60.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": 3.0, "bioavailability": 83.0}, "clinical_statistics": {}}
articleURL: 14
10.1021/jm2007613
{"compound": "3", "ic50_mc": "4 . 8 0", "ki_mc": "7 . 9 2", "kd_mc": "2", "ic50_ce": "2 0", "ed50_an": "7 .", "compound_drug": "pf-02341066"}


{"id": 14, "paper_title": "Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)", "paper_author": ["J. Jean Cui", "Michelle Tran-Dubé", "Hong Shen", "Mitchell Nambu", "Pei-Pei Kung", "Mason Pairish", "Lei Jia", "Jerry Meng", "Lee Funk", "Iriny Botrous", "Michele McTigue", "Neil Grodsky", "Kevin Ryan", "Ellen Padrique", "Gordon Alton", "Sergei Timofeevski", "Shinji Yamazaki", "Qiuhua Li", "Helen Zou", "James Christensen", "Barbara Mroczkowski", "Steve Bender", "Robert S. Kania", "Martin P. Edwards"], "paper_year": 2011, "paper_institution": "La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States", "paper_cited": 539, "doi": "10.1021/jm2007613", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm2007613/production/images/large/jm-2011-007613_0019.jpeg", "compound_count": 73, "compound_name": "3", "compound_name_drug": "PF-02341066", "compound_smiles": "Clc1c([C@@H](C)Oc2cc(c3cnn(c3)C3CCNCC3)cnc2N)c(Cl)c(F)cc1", "medicinal_chemistry_metrics": {"Ki": 7.92, "Kd": 2.0, "IC50": 4.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 20.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {"p1_company_num": 51, "p1_stat_company_num": [0, 3, 0, 2, 0, 1, 44, 0, 1], "p1_company": [[], ["Shanghai Eastern Hospital", "Children's Hospital of Philadelphia", "M.D. Anderson Cancer Center"], [], ["Dana-Farber Cancer Institute", "Hospital 12 de Octubre"], [], ["Baylor College of Medicine"], ["National Cancer Institute (NCI)", "St Bart's Hospital", "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine", "Princess Margaret Cancer Centre", "University of Milano Bicocca", "Southwest Oncology Group", "Department of Oncology, Herlev and Gentofte Hospital", "Atrium Health (formerly Carolinas HealthCare System)", "University of California, San Francisco", "Bristol-Myers Squibb", "The Netherlands Cancer Institute", "Takeda", "Novartis Pharmaceuticals", "Second Affiliated Hospital of Nanchang University", "University of Birmingham", "NRG Oncology", "Oxford University Hospital NHS Trust", "Massachusetts General Hospital", "Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia", "University of Colorado, Denver", "Lyon - URCOT", "Shanghai Pulmonary Hospital, Shanghai, China", "Hunan Province Tumor Hospital", "Children's Oncology Group", "Samsung Medical Center", "Hoffmann-La Roche", "Pfizer", "Guangdong Association of Clinical Trials", "Universitaire Ziekenhuizen Leuven", "Gustave Roussy, Villejuif", "COG Phase I Consortium", "ECOG-ACRIN Cancer Research Group", "St. Jude Children's Research Hospital", "University of Alabama at Birmingham", "Sun Yat-sen University", "Memorial Sloan Kettering Cancer Center", "Associate Professor of Medicine at the Columbia University Medical Center", "Gustave Roussy, Cancer Campus, Grand Paris", "National Cheng-Kung University Hospital", "Uniklinik Köln, Department I for Internal Medicine, LCGC", "Oslo University Hospital", "Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada", "Grenoble - CHU", "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"], [], ["Cancer Hospital of Chines Academy of Medical Sciences"]], "p1_terminate_reason": {"Pfizer": "Death"}, "p1_withdraw_reason": {}, "p1_adverse_event": {"Pfizer": 0.0}, "p2_company_num": 41, "p2_stat_company_num": [3, 17, 0, 5, 0, 2, 12, 0, 2], "p2_company": [["Second Affiliated Hospital of Nanchang University", "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", "National Cheng-Kung University Hospital"], ["Shanghai Pulmonary Hospital, Shanghai, China", "Hunan Province Tumor Hospital", "Samsung Medical Center", "St Bart's Hospital", "Princess Margaret Cancer Centre", "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine", "Guangdong Association of Clinical Trials", "Department of Oncology, Herlev and Gentofte Hospital", "ECOG-ACRIN Cancer Research Group", "University of California, San Francisco", "University of Alabama at Birmingham", "The Netherlands Cancer Institute", "University of Birmingham", "Massachusetts General Hospital", "Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada", "Grenoble - CHU", "Lyon - URCOT"], [], ["Associate Professor of Medicine at the Columbia University Medical Center", "University of Milano Bicocca", "NRG Oncology", "Universitaire Ziekenhuizen Leuven", "Gustave Roussy, Villejuif"], [], ["Atrium Health (formerly Carolinas HealthCare System)", "Southwest Oncology Group"], ["Sun Yat-sen University", "Takeda", "Children's Oncology Group", "Novartis Pharmaceuticals", "National Cancer Institute (NCI)", "Hoffmann-La Roche", "Pfizer", "Gustave Roussy, Cancer Campus, Grand Paris", "COG Phase I Consortium", "Oslo University Hospital", "University of Colorado, Denver", "Bristol-Myers Squibb"], [], ["Uniklinik Köln, Department I for Internal Medicine, LCGC", "Ospedale Santa Maria della Misericordia - Azienda Ospedaliera di Perugia"]], "p2_terminate_reason": {"Atrium Health (formerly Carolinas HealthCare System)": "Death", "NRG Oncology": "Protocol Violation"}, "p2_withdraw_reason": {}, "p2_adverse_event": {"Pfizer": 0.5056285178236398, "COG Phase I Consortium": 0.5, "Atrium Health (formerly Carolinas HealthCare System)": 0.3333333333333333, "NRG Oncology": 0.07142857142857142, "Novartis Pharmaceuticals": 0.4032258064516129, "Takeda": 0.5321100917431193, "Hoffmann-La Roche": 0.2826086956521739, "Massachusetts General Hospital": 0.3333333333333333, "Bristol-Myers Squibb": 0.46153846153846156, "National Cancer Institute (NCI)": 1.0}, "p3_company_num": 6, "p3_stat_company_num": [1, 3, 0, 2, 0, 0, 0, 0, 0], "p3_company": [["Hoffmann-La Roche"], ["Sun Yat-sen University", "Takeda", "Children's Oncology Group"], [], ["Pfizer", "Novartis Pharmaceuticals"], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {"Pfizer": 0.4423076923076923}}}
articleURL: 15
10.1021/jm400402q
{"compound": "15b", "ic50_mc": "2", "kd_mc": "1", "compound_drug": "ldk378"}


{"id": 15, "paper_title": "Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials", "paper_author": ["Thomas H. Marsilje", "Wei Pei", "Bei Chen", "Wenshuo Lu", "Tetsuo Uno", "Yunho Jin", "Tao Jiang", "Sungjoon Kim", "Nanxin Li", "Markus Warmuth", "Yelena Sarkisova", "Frank Sun", "Auzon Steffy", "AnneMarie C. Pferdekamper", "Allen G. Li", "Sean B. Joseph", "Young Kim", "Bo Liu", "Tove Tuntland", "Xiaoming Cui", "Nathanael S. Gray", "Ruo Steensma", "Yongqin Wan", "Jiqing Jiang", "Greg Chopiuk", "Jie Li", "W. Perry Gordon", "Wendy Richmond", "Kevin Johnson", "Jonathan Chang", "Todd Groessl", "You-Qun He", "Andrew Phimister", "Alex Aycinena", "Christian C. Lee", "Badry Bursulaya", "Donald S. Karanewsky", "H. Martin Seidel", "Jennifer L. Harris", "Pierre-Yves Michellys"], "paper_year": 2013, "paper_institution": "Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, United States", "paper_cited": 249, "doi": "10.1021/jm400402q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-14/jm400402q/production/images/large/jm-2013-00402q_0010.jpeg", "compound_count": 56, "compound_name": "15b", "compound_name_drug": "", "compound_smiles": "c1(C2CCNCC2)c(C)cc(Nc2ncc(Cl)c(Nc3c(S(=O)(=O)C(C)C)cccc3)n2)c(OC(C)C)c1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.0, "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 20
10.1021/jm060380k
{"compound": "", "ic50_mc": "2 . 5 μm", "ki_mc": "6 3", "kd_mc": "5", "selectivity_mc": "1", "ic50_ce": "5 2 . 5 proliferation7 . 1 ± 1 . 0 1 . 0 ± 0 . 0 7 2 . 0 ± 0 . 3 9 . 1 ± 1 . 1 0 . 2 ± 0 . 0 2 1 . 8 ± 0 . 1a", "ec50_ce": "3", "herg_ce": "1 2 0", "solubility_ce": "2", "ed50_an": "7 8 9 ) and c-kit ( residues 6 8 9 to 7 6 3 ) were removed , and the subsequent numbering of these sequences was changed accordingly . the figure was prepared using texshade . 46high resolution imagedownload ms powerpoint slide figure 2 chemical structures of imatinib ( a ) , pd173955 ( b ) , and ski-606 ( c ) . high resolution imagedownload ms powerpoint slide", "bioavailability_an": "1 6 in addition , these inhibitors are unable to effectively inhibit the t315i bcr/abl mutant22 , 2 5 ( gambacorti-passerini , c . , unpublished results ) , highlighting the importance of the gatekeeper residue in the binding of these compounds to the atp pocket", "compound_drug": "pd173955"}


{"id": 16, "paper_title": "Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling", "paper_author": ["Rosalind H. Gunby", "Shaheen Ahmed", "Roberta Sottocornola", "Marc Gasser", "Sara Redaelli", "Luca Mologni", "Carmen J Tartari", "Valentina Belloni", "Carlo Gambacorti-Passerini", "Leonardo Scapozza"], "paper_year": 2006, "paper_institution": "Department of Clinical Medicine, Via Cadore 48, University of Milano-Bicocca, Monza, 20052, Italy, Pharmaceutical Biochemistry Group, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Quai Ernest-Ansermet 30, CH-1211 Geneva 4, Switzerland, Department of Experimental Oncology, Istituto Nazionale dei Tumori, Via Venezian 1, Milan, 20133, Italy, and Department of Oncology, McGill University, Montreal, Canada ", "paper_cited": 26, "doi": "10.1021/jm060380k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-19/jm060380k/production/images/large/jm060380kn00001.jpeg", "compound_count": 13, "compound_name": "+", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 63.0, "Kd": 5.0, "IC50": 2500.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 52.5, "EC50": 3.0, "selectivity": "", "hERG": 120.0, "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 0.789, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 16.0}, "clinical_statistics": {}}
articleURL: 21
10.1021/jm201550q
{"compound": "25b", "ic50_mc": "4", "kd_mc": "2", "selectivity_mc": "1", "bioavailability_an": "7 1"}


{"id": 17, "paper_title": "Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase", "paper_author": ["Diane E. Gingrich", "Joseph G. Lisko", "Matthew A. Curry", "Mangeng Cheng", "Matthew Quail", "Lihui Lu", "Weihua Wan", "Mark S. Albom", "Thelma S. Angeles", "Lisa D. Aimone", "R. Curtis Haltiwanger", "Kevin Wells-Knecht", "Gregory R. Ott", "Arup K. Ghose", "Mark A. Ator", "Bruce Ruggeri", "Bruce D. Dorsey"], "paper_year": 2012, "paper_institution": "Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States", "paper_cited": 25, "doi": "10.1021/jm201550q", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0006.jpeg", "compound_count": 38, "compound_name": "25b", "compound_name_drug": "", "compound_smiles": "O=C(N)[C@H]1C2C=C[C@H]([C@H]1Nc1nc(Nc3c(c4CC[C@@H](N5CCOCC5)CCc4cc3)OC)ncc1Cl)C2", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 4.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 71.0}, "clinical_statistics": {}}
articleURL: 22
10.1021/jm050824x
{"compound": "", "ic50_mc": "2", "ki_mc": "8 0", "kd_mc": "7 2 4 compounds , was carefully designed and synthesized using solid-phase chemistry , as shown in scheme 1 . this approach has the following advantages: ( i ) rapid access to a range of individual compounds; ( ii", "selectivity_mc": "i ) rapid access to a range of individual compounds; ( ii ) it provides a flexible means to introduce the desired diversity and to explore the available chemical space; ( iii", "ic50_ce": "8 0 °c; iii . aq . naoh ( 1m ) , thf , 5 0 °c; iv . rnh2 , hatu , diea , dmf; v . tfa/dcm ( 1 0 % ) , 2", "kd_ce": "2 4 compounds , from a virtual library of 7", "ec50_ce": "7", "selectivity_ce": "1 0", "solubility_ce": "7 2 4 compounds , was carefully designed and synthesized using solid-phase chemistry , as shown in scheme 1 . this approach has the following advantages: ( i ) rapid access to a range of individual compounds; ( ii ) it provides a flexible means to introduce the desired diversity and to explore the available chemical space; ( iii ) it achieves the synthesis of the desired final library compounds that cannot be accessed by solution phase chemistry in the same time frame; and ( iv ) the chemistry that is developed can be quickly utilized to access the next generations of focused libraries . after the successful development of this solid-phase chemistry and library synthesis , several compounds were confirmed to be inhibitors of alk with submicromolar potency in our in vitro kinase inhibition assay . the methodology and the scope of the chemistry , as well as its application for library synthesis , will be discussed in detail elsewhere . 4 3", "ed50_an": "7 2 4 compounds , was carefully designed and synthesized using solid-phase chemistry , as shown in scheme 1 . this approach has the following advantages: ( i ) rapid access to a range of individual compounds; ( ii ) it provides a flexible means to introduce the desired diversity and to explore the available chemical space; ( iii ) it achieves the synthesis of the desired final library compounds that cannot be accessed by solution phase chemistry in the same time frame; and ( iv ) the chemistry that is developed can be quickly utilized to access the next generations of focused libraries . after the successful development of this solid-phase chemistry and library synthesis , several compounds were confirmed to be inhibitors of alk with submicromolar potency in our in vitro kinase inhibition assay . the methodology and the scope of the chemistry , as well as its application for library synthesis , will be discussed in detail elsewhere . 4 3 scheme 1 . solid-phase synthesis of pyridone focused libraryaa reagents and conditions: i . wang resin , pph3 , dead , thf; ii . r3b ( oh ) 2 , pd ( pph3 ) 4 , na2co3 , toluene/water ( 3/1 , v/v ) , 8 0 °c; iii . aq . naoh ( 1m", "bioavailability_an": "6 2 %", "compound_drug": "pph3 ) 4 , na2co3 , toluene/water ( 3/1"}


{"id": 18, "paper_title": "Design and Synthesis of 5-Aryl-pyridone-carboxamides as Inhibitors of Anaplastic Lymphoma Kinase", "paper_author": ["Rongshi Li", "Liquan Xue", "Tong Zhu", "Qin Jiang", "Xiaoli Cui", "Zheng Yan", "Danny McGee", "Jian Wang", "Vidyasagar Reddy Gantla", "Jason C. Pickens", "Doug McGrath", "Alexander Chucholowski", "Stephan W. Morris", "Thomas R. Webb"], "paper_year": 2006, "paper_institution": "ChemBridge Research Laboratories and ChemBridge Corporation, 16981 Via Tazon, Suites K and G, San Diego, California 92127, and Departments of Pathology and Hematology-Oncology, St. Jude Children's Research Hospital, 332 N. Lauderdale Street, Memphis, Tennessee 38105 ", "paper_cited": 41, "doi": "10.1021/jm050824x", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-3/jm050824x/production/images/large/jm050824xn00001.jpeg", "compound_count": 72, "compound_name": "9c", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 80.0, "Kd": 724.0, "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 24.0, "IC50": 80.0, "EC50": 7.0, "selectivity": "", "hERG": "", "solubility": 0.724}, "pharm_metrics_vivo": {"ED50": 0.724, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 62.0}, "clinical_statistics": {}}
articleURL: 23
10.1021/jm201565s
{"compound": "1", "ic50_mc": "1 7 4", "ic50_ce": "2", "ed50_an": "1 1 ) fret assays monitoring phosphorylation of a peptide substrate were also used for the counter-screening assay for igf1r .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion analogues were assayed for inhibition of alk enzyme activity as well as selectivity over igf1r . ( 2 4 ) alk functional activity was measured using a time-resolved fluorescence resonance energy transfer ( tr-fret ) assay which measured the phosphorylation of a peptide substrate . ( 1 1 ) fret assays monitoring phosphorylation of a peptide substrate were also used for the counter-screening assay for igf1r ."}


{"id": 19, "paper_title": "Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors", "paper_author": ["Marian C. Bryan", "Douglas A. Whittington", "Elizabeth M. Doherty", "James R. Falsey", "Alan C. Cheng", "Renee Emkey", "Rachael L. Brake", "Richard T. Lewis"], "paper_year": 2012, "paper_institution": "Medicinal Chemistry Research Technologies, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States", "paper_cited": 24, "doi": "10.1021/jm201565s", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-4/jm201565s/production/images/large/jm-2011-01565s_0004.jpeg", "compound_count": 46, "compound_name": "1", "compound_name_drug": "", "compound_smiles": "O(c1c(OC)c(OC)cc(Nc2nc(ccn2)N2CCC[C@@H](C2)C(=O)NCc2ccc(cc2)C)c1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 174.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.011, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 24
10.1021/acs.jmedchem.0c01550
{"compound": "cj-2360", "ic50_mc": "2 . 2", "selectivity_mc": "1", "ic50_ce": "5 1 4 . 6", "ed50_an": "7 ) we selected alectinib ( 3 ) as the template for the design of a new class of alk inhibitors .", "t_half_an": "2 4", "bioavailability_an": "3 8 . 2"}


{"id": 20, "paper_title": "Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression", "paper_author": ["Jianyong Chen", "Yunlong Zhou", "Xuyuan Dong", "Liu Liu", "Longchuan Bai", "Donna McEachern", "Sally Przybranowski", "Chao-Yie Yang", "Jeanne Stuckey", "Xiaoqin Li", "Bo Wen", "Ting Zhao", "Siwei Sun", "Duxin Sun", "Lingling Jiao", "Yu Jing", "Ming Guo", "Dajun Yang", "Shaomeng Wang"], "paper_year": 2020, "paper_institution": "Rogel Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States", "paper_cited": 1, "doi": "10.1021/acs.jmedchem.0c01550", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01550/20201120/images/large/jm0c01550_0020.jpeg", "compound_count": 57, "compound_name": "cj-2360", "compound_name_drug": "", "compound_smiles": "N1(C[C@@H](N([C@@H](C1)C)C)C)c1c(OC)cc2c(=O)c3c4ccc(C#N)cc4[nH]c3n(C(C)C)c2c1F", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 2.2, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 514.6, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": 24.0, "bioavailability": 38.2}, "clinical_statistics": {}}
articleURL: 25
10.1021/acs.jmedchem.5b01136
{"compound": "", "ic50_mc": "2", "ki_mc": "1", "ed50_an": "1 μm ( table 2 ) . compounds that showed potent inhibition of the g1202r mutant without showing potent inhibition of untransduced ba/f3 cells in the single-point inhibition assay were then taken forward and tested against a panel of the most common secondary alk mutants to determine cellular phospho-alk ic50 values ( table 3 ) .", "bioavailability_an": "1 6 ) . we hypothesized that these compounds might be active because they were smaller and possess a basic nitrogen capable of forming a hydrogen bond with the guanidine moiety of the 1202r . compounds 7 , 8 , and 9 were quite potent against the g1202r mutant in a single-point inhibition assay at a concentration of 1 μm . compounds lacking a basic nitrogen ( 1 1 and 1 2 ) showed much less inhibitory activity . compounds 7 , 8 , and 9 were then tested against a panel of the most common secondary alk mutants to obtain ic50 values , where we found that these compounds were indeed potent against the g1202r mutant with ic50 values ranging from 2 1 to 3 2", "compound_drug": "jh-viii-157-02"}


{"id": 21, "paper_title": "Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation", "paper_author": ["John M. Hatcher", "Magda Bahcall", "Hwan Geun Choi", "Yang Gao", "Taebo Sim", "Rani George", "Pasi A. Jänne", "Nathanael S. Gray"], "paper_year": 2015, "paper_institution": "†Department of Cancer Biology, ‡Lowe Center for Thoracic Oncology, and §Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02115, United States", "paper_cited": 25, "doi": "10.1021/acs.jmedchem.5b01136", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01136/20151204/images/large/jm-2015-01136d_0015.jpeg", "compound_count": 36, "compound_name": "6", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 1.0, "Kd": "", "IC50": 2.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 1.0, "AUC": "μm150478", "solubility": "", "t_half": "", "bioavailability": 16.0}, "clinical_statistics": {}}
articleURL: 26
10.1021/acs.jmedchem.6b00306
{"compound": "brigatinib", "ic50_mc": "0 . 4", "ed50_an": "7 ( tae684 , figure 1 ) , ( 4 8 ) had been reported . further optimization of 7 to address selectivity and potential idiosyncratic toxicity issues led to the eventual discovery of ceritinib a few years later . ( 1 7 )", "t_half_an": "1", "bioavailability_an": "3 9 %", "compound_drug": "ap26113"}


{"id": 22, "paper_title": "Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase", "paper_author": ["Wei-Sheng Huang", "Shuangying Liu", "Dong Zou", "Mathew Thomas", "Yihan Wang", "Tianjun Zhou", "Jan Romero", "Anna Kohlmann", "Feng Li", "Jiwei Qi", "Lisi Cai", "Timothy A. Dwight", "Yongjin Xu", "Rongsong Xu", "Rory Dodd", "Angela Toms", "Lois Parillon", "Xiaohui Lu", "Rana Anjum", "Sen Zhang", "Frank Wang", "Jeffrey Keats", "Scott D. Wardwell", "Yaoyu Ning", "Qihong Xu", "Lauren E. Moran", "Qurish K. Mohemmad", "Hyun Gyung Jang", "Tim Clackson", "Narayana I. Narasimhan", "Victor M. Rivera", "Xiaotian Zhu", "David Dalgarno", "William C. Shakespeare"], "paper_year": 2016, "paper_institution": "ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, Massachusetts 02139, United States", "paper_cited": 155, "doi": "10.1021/acs.jmedchem.6b00306", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-10/acs.jmedchem.6b00306/20160520/images/large/jm-2016-00306u_0005.jpeg", "compound_count": 58, "compound_name": "brigatinib", "compound_name_drug": "AP26113", "compound_smiles": "C1CN(CCN1C)C1CCN(CC1)c1ccc(c(OC)c1)Nc1nc(Nc2ccccc2P(O)(C)C)c(cn1)Cl", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 0.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": 1.0, "bioavailability": 39.0}, "clinical_statistics": {"p1_company_num": 13, "p1_stat_company_num": [0, 1, 0, 0, 0, 0, 12, 0, 0], "p1_company": [[], ["Northwestern University"], [], [], [], [], ["Takeda", "Princess Maxima Center for Pediatric Oncology in The Netherlands", "Ohio State University Comprehensive Cancer Center", "NRG Oncology", "Fundación GECP President", "Duke University", "Massachusetts General Hospital", "Institut für Klinische Krebsforschung IKF GmbH", "University of California, San Francisco", "Ariad Pharmaceuticals", "Fondazione per la Medicina Personalizzata", "Lyon - URCOT"], [], []], "p1_terminate_reason": {}, "p1_withdraw_reason": {}, "p1_adverse_event": {}, "p2_company_num": 12, "p2_stat_company_num": [1, 8, 0, 2, 0, 0, 1, 0, 0], "p2_company": [["Princess Maxima Center for Pediatric Oncology in The Netherlands"], ["Fundación GECP President", "Duke University", "Massachusetts General Hospital", "Institut für Klinische Krebsforschung IKF GmbH", "University of California, San Francisco", "Ohio State University Comprehensive Cancer Center", "Fondazione per la Medicina Personalizzata", "Lyon - URCOT"], [], ["NRG Oncology", "Ariad Pharmaceuticals"], [], [], ["Takeda"], [], []], "p2_terminate_reason": {}, "p2_withdraw_reason": {}, "p2_adverse_event": {"Takeda": 0.5321100917431193}, "p3_company_num": 1, "p3_stat_company_num": [0, 1, 0, 0, 0, 0, 0, 0, 0], "p3_company": [[], ["Takeda"], [], [], [], [], [], [], []], "p3_terminate_reason": {}, "p3_withdraw_reason": {}, "p3_adverse_event": {}}}
articleURL: 27
10.1021/jm200652u
{"compound": "13d", "selectivity_mc": "1", "ic50_ce": "2", "ed50_an": "3 % ) . ( 2 2 ) the region often serves as an entrance for ligand binding , and alk is considered to have a wide-open surface for binding of a ligand . therefore , we considered that the steric repulsion between a ligand and the amino acid residues of the e0 region of off-target proteins should afford high alk selectivity .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion molecular design since our previous study ( 1 8 ) revealed that the alk inhibitors bearing a 6 , 6-dimethyl-11-oxo-6 , 11-dihydro-5h-benzo[b]carbazole scaffold were atp competitive , we investigated the amino acid sequences surrounding the atp-binding site of several kinases . we found that the amino acid residues of the e0 region ( 2 1 ) of alk ( a1200"}


{"id": 23, "paper_title": "9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors", "paper_author": ["Kazutomo Kinoshita", "Takamitsu Kobayashi", "Kohsuke Asoh", "Noriyuki Furuichi", "Toshiya Ito", "Hatsuo Kawada", "Sousuke Hara", "Jun Ohwada", "Kazuo Hattori", "Takuho Miyagi", "Woo-Sang Hong", "Min-Jeong Park", "Kenji Takanashi", "Toshiyuki Tsukaguchi", "Hiroshi Sakamoto", "Takuo Tsukuda", "Nobuhiro Oikawa"], "paper_year": 2011, "paper_institution": "Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan", "paper_cited": 53, "doi": "10.1021/jm200652u", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2011/jmcmar.2011.54.issue-18/jm200652u/production/images/large/jm-2011-00652u_0009.jpeg", "compound_count": 24, "compound_name": "13d", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.003, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 28
10.1021/jm401805h
{"compound": "8e", "kd_mc": "1 . 3", "bioavailability_an": "8 6"}


{"id": 24, "paper_title": "Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib", "paper_author": ["Qinhua Huang", "Ted W. Johnson", "Simon Bailey", "Alexei Brooun", "Kevin D. Bunker", "Benjamin J. Burke", "Michael R. Collins", "Andrew S. Cook", "J. Jean Cui", "Kevin N. Dack", "Judith G. Deal", "Ya-Li Deng", "Dac Dinh", "Lars D. Engstrom", "Mingying He", "Jacqui Hoffman", "Robert L. Hoffman", "Patrick S. Johnson", "Robert S. Kania", "Hieu Lam", "Justine L. Lam", "Phuong T. Le", "Qiuhua Li", "Laura Lingardo", "Wei Liu", "Melissa West Lu", "Michele McTigue", "Cynthia L. Palmer", "Paul F. Richardson", "Neal W. Sach", "Hong Shen", "Tod Smeal", "Graham L. Smith", "Albert E. Stewart", "Sergei Timofeevski", "Konstantinos Tsaparikos", "Hui Wang", "Huichun Zhu", "Jinjiang Zhu", "Helen Y. Zou", "Martin P. Edwards"], "paper_year": 2014, "paper_institution": "La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States", "paper_cited": 67, "doi": "10.1021/jm401805h", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-4/jm401805h/production/images/large/jm-2013-01805h_0021.jpeg", "compound_count": 53, "compound_name": "8e", "compound_name_drug": "", "compound_smiles": "c1(c(ncc(c1)c1cnn(c1)C1CCNCC1)N)O[C@@H](c1c(c(F)ccc1Cl)Cl)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.3, "IC50": "=0.8 nM", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "0.8", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 86.0}, "clinical_statistics": {}}
articleURL: 29
10.1021/acs.jmedchem.7b01039
{"compound": "crizotinib came into existence , requiring mutation-targeting drug discovery for the powerful second-line treatment . in this study , we report 4-phenoxyquinoline-based inhibitors that overcome crizotinib resistance to alk l1196m , discovered by the fragment-growing strategy . the protonation of 4-aminoquinoline core could", "ki_mc": "2 2 nm", "ic50_ce": "2", "selectivity_ce": "1", "solubility_ce": "3 1", "ed50_an": "1a shows the lowest energy conformation as calculated with the discovery studio 4 . 5 software . on the basis of comparing structural features and the interactions formed between various fragments and the l1196m mutant , the 4-aminoquinoline core appeared to be stabilized through hydrogen bonding with the backbone amide groups of a residue in the hinge region ( met1199 ) of the atp-binding site . interestingly , a larger gatekeeper met1196 residue was found at the interface formed by van der waals contacts between 4-aminoquinoline and the l1196m mutant ( figure 1b ) , indicating that favorable hydrophobic interactions were formed in the l1196m mutant . the quinoline serves as a hydrogen-bond acceptor with the backbone amidic nitrogen of met1199 in the middle of the hinge region , whereas the six-membered bicyclic aromatic ring of quinoline seems to be further stabilized through the van der waals contacts of its aromatic rings with the side chains of leu1122 , ala1148 , and leu1256 . it is noteworthy that in the l1196m mutant , the increased steric hindrance of the gatekeeper mutation", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion identification of 4-aminoquinoline moiety with the goal of developing a new structural class of potent l1196m mutant inhibitors , we investigated the starting structure for de novo design and the affinity of various hinge-binding scaffolds to accommodate the increased bulk of the side chain of met1196 in the atp binding site , employing an l1196m crystal structure ( pdb 2yfx ) as a template . figure 1a shows the lowest energy conformation as calculated with the discovery studio 4 . 5 software . on the basis of comparing structural features and the interactions formed between various fragments and the l1196m mutant , the 4-aminoquinoline core appeared to be stabilized through hydrogen bonding with the backbone amide groups of a residue in the hinge region ( met1199"}


{"id": 25, "paper_title": "Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design", "paper_author": ["Shinmee Mah", "Jung Hee Park", "Hoi-Yun Jung", "Kukcheol Ahn", "Soyeon Choi", "Hyun Seop Tae", "Kyung Hee Jung", "Jin Kyung Rho", "Jae Cheol Lee", "Soon-Sun Hong", "Sungwoo Hong"], "paper_year": 2017, "paper_institution": "Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Korea", "paper_cited": 12, "doi": "10.1021/acs.jmedchem.7b01039", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-22/acs.jmedchem.7b01039/20171117/images/large/jm-2017-01039t_0016.jpeg", "compound_count": 33, "compound_name": "30", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 22.0, "Kd": "", "IC50": "μm0.0071", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": 31.0}, "pharm_metrics_vivo": {"ED50": 0.0045, "AUC": "155.1", "solubility": "", "t_half": "3.5", "bioavailability": " "}, "clinical_statistics": {}}
articleURL: 30
10.1021/acs.jmedchem.0c01707
{"compound": "con b-1", "ic50_mc": "1 . 4", "ic50_ce": "3 0", "t_half_an": "2 . 8 9 h .", "bioavailability_an": "1 2 . 1 %", "compound_drug": "cys1259"}


{"id": 26, "paper_title": "Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design", "paper_author": ["Guoyi Yan", "Xinxin Zhong", "Chunlan Pu", "Lin Yue", "Huifang Shan", "Suke Lan", "Meng Zhou", "Xueyan Hou", "Jie Yang", "Deyu Li", "Shilong Fan", "Rui Li"], "paper_year": 2021, "paper_institution": "State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, China", "paper_cited": 1, "doi": "10.1021/acs.jmedchem.0c01707", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01707/20210204/images/large/jm0c01707_0013.jpeg", "compound_count": 24, "compound_name": "conb-1", "compound_name_drug": "conb-1", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.4, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 30.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": 2.89, "bioavailability": 12.1}, "clinical_statistics": {}}
articleURL: 31
10.1021/acs.jmedchem.6b01679
{"compound": "1", "selectivity_mc": "<unk> . in this paragraph , can you find out the result of selectivity_mc", "ic50_ce": "3 . 3 5 μm", "ed50_an": "1 ( schemes 1 and 2 ) , which contains a saturated ketone group in place of the cis-enone moiety that is present in l-783277 . we anticipated that 1 would be a reversibly binding version of l-783277 . in addition , we synthesized the two isomeric trihydroxy analogues of l-783277 , 1 3 and 1 4 , analogue 1 5 containing an external olefin group , and the lactam derivative 2 5 in order to carry out sar analysis .", "t_half_an": "2", "compound_drug": "l-783277"}


{"id": 27, "paper_title": "Identification of the First Selective Activin Receptor-Like Kinase 1 Inhibitor, a Reversible Version of L-783277", "paper_author": ["Hanna Cho", "Sandip Sengupta", "Sean S. H. Jeon", "Wooyoung Hur", "Hwan Geun Choi", "Hong-Seog Seo", "Byung Joo Lee", "Jeong Hun Kim", "Minhwan Chung", "Noo Li Jeon", "Nam Doo Kim", "Taebo Sim"], "paper_year": 2017, "paper_institution": "KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea", "paper_cited": 3, "doi": "10.1021/acs.jmedchem.6b01679", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01679/20170216/images/large/jm-2016-01679v_0008.jpeg", "compound_count": 28, "compound_name": "1", "compound_name_drug": "L-783277", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 3350.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.001, "AUC": "", "solubility": "", "t_half": 2.0, "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 33
10.1021/acs.jmedchem.1c00373
{"compound": "brigatinib degrader siais164018 with destroying metastasis-related oncoproteins and a reshuffling kinome profile proteolysis-targeting chimera ( protac ) is an attractive technology in drug discovery . canonically , targets act as a basic starting point in the most previous protac design . here , we designed degraders considering from the view of clinical benefits . with this novel design , brigatinib was turned into a degrader siais164018 and endowed with unique features . first , siais164018 could degrade not only alk fusion proteins in activating or g1202r-mutated form", "ic50_mc": "6 . 8", "selectivity_mc": "1", "ic50_ce": "5 0 0 nm", "ed50_an": "6 ( siais164018 ) degraded alk significantly at 1 0 nm and it had been identified as a potent brigatinib-based degrader (", "compound_drug": "mda-mb-231"}


{"id": 28, "paper_title": "Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile", "paper_author": ["Chaowei Ren", "Ning Sun", "Haixia Liu", "Ying Kong", "Renhong Sun", "Xing Qiu", "Jinju Chen", "Yan Li", "Jianshui Zhang", "Yuedong Zhou", "Hui Zhong", "Qianqian Yin", "Xiaoling Song", "Xiaobao Yang", "Biao Jiang"], "paper_year": 2021, "paper_institution": "Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China", "paper_cited": -1, "doi": "10.1021/acs.jmedchem.1c00373", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/acs.jmedchem.1c00373/20210629/images/large/jm1c00373_0012.jpeg", "compound_count": 6, "compound_name": "1–11", "compound_name_drug": "Brigatinib Degrader SIAIS164018", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 6.8, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 500.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.006, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 34
10.1021/acs.jmedchem.0c00507
{"compound": "", "ic50_mc": "six", "ki_mc": "we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues", "selectivity_mc": "<unk> . in this paragraph , can you find out the result of selectivity_mc ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis ) has become a major", "ic50_ce": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein", "kd_ce": "<unk> . in this paragraph , can you find out the result of kd_ce ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis", "ed50_an": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein , we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues , and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors . additionally , we also briefly describe allosteric kinase inhibitors and proteolysis targeting chimera ( protac ) as two other potential strategies while addressing future opportunities in this area . . [SEP]", "t_half_an": "six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m . herein , we summarize the major medicinal chemistry strategies employed in the discovery of these representative smkis , such as avoiding steric hindrance , making additional interactions with mutated residues , and forming a covalent bond with an active site cysteine to override resistance observed for reversible inhibitors", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] [CLS] what is the compound in this paper ? [SEP] medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations clinically acquired resistance to small molecule kinase inhibitors ( smkis ) has become a major “unmet clinical need” in cancer therapy . to date , there are six smkis to be approved for the treatment of cancer patients through targeting of clinically acquired resistance caused by on-target mutations . these are mainly focused on the mutant kinases bcr-abl t315i , egfr t790m , and alk l1196m"}


{"id": 29, "paper_title": "Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations", "paper_author": ["Xiaoyun Lu", "Jeff B. Smaill", "Ke Ding"], "paper_year": 2020, "paper_institution": "International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China", "paper_cited": 7, "doi": "10.1021/acs.jmedchem.0c00507", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-19/acs.jmedchem.0c00507/20201019/images/large/jm0c00507_0013.jpeg", "compound_count": 29, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 36
10.1021/acs.jmedchem.7b00076
{"compound": "3m", "ic50_mc": "3", "kd_mc": "2", "ic50_ce": "2 4 . 8", "bioavailability_an": "6 0 %", "compound_drug": "25-33 ) the crystal structure of fgfr1 in complex with potency inhibitor 1 5 ( pdb id: 3tt0 ) ( 3 4"}


{"id": 30, "paper_title": "Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer", "paper_author": ["Wei Zhu", "Hui Chen", "Yulan Wang", "Jiang Wang", "Xia Peng", "Xianjie Chen", "Yinglei Gao", "Chunpu Li", "Yulong He", "Jing Ai", "Meiyu Geng", "Mingyue Zheng", "Hong Liu"], "paper_year": 2017, "paper_institution": "†State Key Laboratory of Drug Research and ‡CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 201203, China", "paper_cited": 14, "doi": "10.1021/acs.jmedchem.7b00076", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-14/acs.jmedchem.7b00076/20170721/images/large/jm-2017-00076u_0015.jpeg", "compound_count": 73, "compound_name": "3m", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 2.0, "IC50": 3.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 24.8, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": 60.0}, "clinical_statistics": {}}
articleURL: 47
10.1021/jm0400247
{"compound": "1 9", "ic50_mc": "3 . 2 1", "kd_mc": "1 . 1 4 å", "selectivity_mc": "1", "ed50_an": "7 4 nm . while presenting some structural analogy with p38 map kinase inhibitors , 1 1 this compound did not exhibit p38 map kinase activity when tested in a relevant binding assay ( ic50 > 1 6 μm ) . a chemistry program was initiated with the aim of increasing potency . to support the study of structure−activity relationships ( sar ) within the series , a binding assay was set up in which the ability of the test compounds to displace a rhodamine green-labeled ligand from recombinant gst-alk5 was measured . in this assay , 1 exhibited an ic50 of 7 2 4 nm . the compounds were evaluated in both the binding and the tgf-β-dependent cellular assay , and the most potent compounds were also tested in the alk5 autophosphorylation assay . at the outset of this work , no structures of alk5 inhibitors cocrystallized with the protein had been published . however , the crystal structure of an inactive form of alk5 complexed to fkbp129 was available and this was used as a basis for docking studies .", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion consideration of the structure of 1 strongly suggested that it might inhibit a kinase , and alk5 appeared a likely candidate . accordingly , an alk5 autophosphorylation assay was constructed using the purified human alk5 kinase domain produced in sf9 insect cells . aminothiazole 1 inhibited alk5 activity in this assay with an ic50 of 2 7 4 nm . while presenting some structural analogy with p38 map kinase inhibitors , 1 1 this compound did not exhibit p38 map kinase activity when tested in a relevant binding assay ( ic50 > 1 6 μm ) . a chemistry program was initiated with the aim of increasing potency . to support the study of structure−activity relationships ( sar ) within the series , a binding assay was set up in which the ability of the test compounds to displace a rhodamine green-labeled ligand from recombinant gst-alk5 was measured . in this assay , 1 exhibited an ic50 of 7 2 4 nm . the compounds were evaluated in both the binding and the tgf-β-dependent cellular assay , and the most potent compounds were also tested in the alk5 autophosphorylation assay . at the outset of this work , no structures of alk5 inhibitors cocrystallized with the protein had been published . however , the crystal structure of an inactive form of alk5 complexed to fkbp129 was available and this was used as a basis for docking studies ."}


{"id": 31, "paper_title": "Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors", "paper_author": ["Françoise Gellibert", "James Woolven", "Marie-Hélène Fouchet", "Neil Mathews", "Helen Goodland", "Victoria Lovegrove", "Alain Laroze", "Van-Loc Nguyen", "Stéphane Sautet", "Ruolan Wang", "Cheryl Janson", "Ward Smith", "Gaël Krysa", "Valérie Boullay", "Anne-Charlotte de Gouville", "Stéphane Huet", "David Hartley"], "paper_year": 2004, "paper_institution": "Departments of Medicinal Chemistry and Biology, GlaxoSmithKline, 25-27 Avenue du Québec, 91951 Les Ulis, France, Discovery Research, Computational and Structural Science, and Department of Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, Discovery Research, Assay Development and Compound Profiling, GlaxoSmithKline, Five Moore Drive, P.O. Box 13398, Research Triangle Park, North Carolina 27709, and Discovery Research, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, Pennsylvania 19406 ", "paper_cited": 126, "doi": "10.1021/jm0400247", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2004/jmcmar.2004.47.issue-18/jm0400247/production/images/large/jm0400247n00001.jpeg", "compound_count": 105, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "c1cc2nc(ccc2nc1)/C(=C(/N=C(/N)\\C)\\C(=C\\C=C/C(=C)C)\\C)/C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": 1.14, "IC50": 3.21, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.074, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 57
10.1021/jm500115w
{"compound": "12b", "ic50_mc": "0 . 0 3 μm", "ki_mc": "2 0 . 5 9 nm", "selectivity_mc": "1", "kd_ce": "2", "solubility_ce": "2 , 4]triazolo[1 , 5-a]pyridin-6-yl ) -5- ( 6-methylpyridin-2-yl ) -1h-imidazol-2-yl", "ed50_an": "1 0 and 1", "bioavailability_an": "6 3", "compound_drug": "ew-7197"}


{"id": 32, "paper_title": "Discovery of N-((4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF-β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent", "paper_author": ["Cheng Hua Jin", "Maddeboina Krishnaiah", "Domalapally Sreenu", "Vura B. Subrahmanyam", "Kota S. Rao", "Hwa Jeong Lee", "So-Jung Park", "Hyun-Ju Park", "Kiho Lee", "Yhun Yhong Sheen", "Dae-Kee Kim"], "paper_year": 2014, "paper_institution": "Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-gu, Seoul 120-750, Korea", "paper_cited": 64, "doi": "10.1021/jm500115w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm500115w/20160122/images/large/jm-2014-00115w_0012.jpeg", "compound_count": 51, "compound_name": "12b", "compound_name_drug": "", "compound_smiles": "c1c(c2c(c3cn4c(ncn4)cc3)nc([nH]2)CNc2c(F)cccc2)nc(cc1)C", "medicinal_chemistry_metrics": {"Ki": 20.59, "Kd": "", "IC50": 30.0, "selectivity": "μm1"}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "μm31.04", "EC50": "", "selectivity": "", "hERG": "", "solubility": 2.0}, "pharm_metrics_vivo": {"ED50": 10.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 63.0}, "clinical_statistics": {}}
articleURL: 64
10.1021/acs.jmedchem.8b00782
{"compound": "", "ic50_mc": "8 . 2 μm;", "ki_mc": "in this paragraph", "kd_mc": "0 . 4 9 .", "selectivity_mc": "1", "ic50_ce": "2", "herg_ce": "paragraph", "ed50_an": "7 and 8 ) represented the most promising compounds so far , with sub-μm potency , good ligand efficiency and low tpsa , we decided to focus further modification on these isomers .", "bioavailability_an": "1 3", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results unfortunately , attempts to solve the structure of 1 bound to alk2 were not successful . however , since 1 did not feature the pyridine substituent of the published alk5 inhibitor ( compound 1 9"}


{"id": 33, "paper_title": "Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure–Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept", "paper_author": ["Liam Hudson", "James Mui", "Santiago Vázquez", "Diana M. Carvalho", "Eleanor Williams", "Chris Jones", "Alex N. Bullock", "Swen Hoelder"], "paper_year": 2018, "paper_institution": "Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom", "paper_cited": 21, "doi": "10.1021/acs.jmedchem.8b00782", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-16/acs.jmedchem.8b00782/20180816/images/large/jm-2018-00782w_0014.jpeg", "compound_count": 35, "compound_name": "16", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 8.2, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": 2.0, "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 0.007, "AUC": "", "solubility": "", "t_half": "", "bioavailability": 13.0}, "clinical_statistics": {}}
articleURL: 95
10.1021/jm010493y
{"compound": "1 4", "ic50_mc": "7", "ki_mc": "8 </b> gave the selective inhibitor <b> 1 4", "selectivity_mc": "7 </b> , a selective alk5 inhibitor . with this information , optimization of the triarylimidazole hit <b> 8 </b> gave the selective inhibitor <b> 1", "kd_ce": "3 , 4-methylenedioxyphenyl group gave <b> 7 </b> , a selective alk5 inhibitor . with this information , optimization of the triarylimidazole hit <b> 8 </b> gave the selective inhibitor <b> 1 4 </b> , which inhibits tgf-β1-induced fibronectin mrna formation while displaying no measurable cytotoxicity in the 4", "ec50_ce": "3", "herg_ce": "1 receptor ( alk5 ) screening of our internal compound collection for inhibitors of the transforming growth factor β1 ( tgf-β1 ) type i receptor ( alk5 ) identified several hits", "ed50_an": "7 </b> , a selective alk5 inhibitor . with this information , optimization of the triarylimidazole hit <b> 8"}


{"id": 34, "paper_title": "Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)", "paper_author": ["James F. Callahan", "Joelle L. Burgess", "James A. Fornwald", "Laramie M. Gaster", "John D. Harling", "Frank P. Harrington", "Jag Heer", "Chet Kwon", "Ruth Lehr", "A. Mathur", "Barbara A. Olson", "Joseph Weinstock", "Nicholas J. Laping"], "paper_year": 2002, "paper_institution": "Department of Medicinal Chemistry, GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, Departments of Medicinal Chemistry, Renal Pharmacology, Protein Biochemistry, and Gene Expression Sciences, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, King of Prussia, Pennsylvania 19406, and Department of Medicinal Chemistry, New Frontiers Science Park (North), Coldharbour Road, Harlow, Essex CM19 5AD, England ", "paper_cited": 237, "doi": "10.1021/jm010493y", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2002/jmcmar.2002.45.issue-5/jm010493y/production/images/large/jm010493yn00001.jpeg", "compound_count": 14, "compound_name": "14", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": 8.0, "Kd": "", "IC50": 7.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 3.0, "IC50": "", "EC50": 3.0, "selectivity": "", "hERG": 0.001, "solubility": ""}, "pharm_metrics_vivo": {"ED50": 7.0, "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
articleURL: 212
10.1021/jm900807w
{"compound": "1 9", "ic50_mc": "1", "kd_ce": "2 , 6-dimethylpyridyl group was therefore identified as the most attractive selectivity pocket group due to its potency and ligand efficiency ( and therefore favorable predicted physicochemical properties ) . simultaneously , we examined the sar of the aniline group ( table 1 ) . thus , ortho substitution by a methoxy group as in 1", "solubility_ce": "7 , 8 , and 9 are all less potent than 6 . the 2 , 6-dimethylpyridyl group was therefore identified as the most attractive selectivity pocket group due to its potency and ligand efficiency ( and therefore favorable predicted physicochemical properties ) . simultaneously , we examined the sar of the aniline group ( table 1 ) . thus , ortho substitution by a methoxy group as in 1", "bioavailability_an": "1 6", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion guided by the x-ray crystallography results , we examined the sar of the 4-pyridinoxy-2-anilinopyridine scaffold with the goal of improving the pk properties and cellular potency of the original hit compound 1 . to assess pk properties , we used in vivo rat pk as we did not have a convincing correlation between in vitro hepatocyte data and in vivo clearance . variation of the phenol group ( table 1"}


{"id": 35, "paper_title": "Rapid Generation of a High Quality Lead for Transforming Growth Factor-β (TGF-β) Type I Receptor (ALK5)†", "paper_author": ["Frederick W. Goldberg", "Richard A. Ward", "Steven J. Powell", "Judit É. Debreczeni", "Richard A. Norman", "Nicola J. Roberts", "Allan P. Dishington", "Helen J. Gingell", "Kate F. Wickson", "Andrew L. Roberts"], "paper_year": 2009, "paper_institution": "AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, U.K.", "paper_cited": 25, "doi": "10.1021/jm900807w", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2009/jmcmar.2009.52.issue-23/jm900807w/production/images/large/jm-2009-00807w_0006.jpeg", "compound_count": 15, "compound_name": "19", "compound_name_drug": "", "compound_smiles": "", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 1.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": 2.0, "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": 7.0}, "pharm_metrics_vivo": {"ED50": "", "AUC": "75 (4.95)", "solubility": "", "t_half": "", "bioavailability": 16.0}, "clinical_statistics": {}}
articleURL: 326
10.1021/jm0509905
{"compound": "13d", "selectivity_mc": "1", "selectivity_ce": "1 5", "auc_an": "1 7 2", "compound_drug": "gw788388"}


{"id": 36, "paper_title": "Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor", "paper_author": ["Françoise Gellibert", "Anne-Charlotte de Gouville", "James Woolven", "Neil Mathews", "Van-Loc Nguyen", "Cécile Bertho-Ruault", "Angela Patikis", "Eugene T. Grygielko", "Nicholas J. Laping", "Stéphane Huet"], "paper_year": 2006, "paper_institution": "Department of Medicinal Chemistry and Biology, GlaxoSmithKline, 25−27 Avenue du Québec, 91951 Les Ulis, France, Computational and Structural Sciences, Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, GunnelsWood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, Department of Medicinal Chemistry, GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom, and Departments of Renal and Urology Research, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania ", "paper_cited": 76, "doi": "10.1021/jm0509905", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2006/jmcmar.2006.49.issue-7/jm0509905/production/images/large/jm0509905n00001.jpeg", "compound_count": 175, "compound_name": "13d", "compound_name_drug": "GW788388", "compound_smiles": "C=C(c1ccc(c2cc(c3c[nH]nc3c3ncccc3)ccn2)cc1)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": "μm0.018 (0.003−0.094) ", "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": 172.0, "solubility": "", "t_half": "1.3", "bioavailability": "17 "}, "clinical_statistics": {}}
articleURL: 356
10.1021/acs.jmedchem.0c01199
{"compound": "<b> ldn-214117", "ic50_mc": "6 8 nm", "ed50_an": "1 . 5 ,", "t_half_an": "3 . 9 1", "bioavailability_an": "9 6 %"}


{"id": 37, "paper_title": "Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma", "paper_author": ["David Smil", "Jong Fu Wong", "Eleanor P. Williams", "Roslin J. Adamson", "Alison Howarth", "David A. McLeod", "Ahmed Mamai", "Soyoung Kim", "Brian J. Wilson", "Taira Kiyota", "Ahmed Aman", "Julie Owen", "Gennady Poda", "Kurumi Y. Horiuchi", "Ekaterina Kuznetsova", "Haiching Ma", "J. Nicole Hamblin", "Sue Cramp", "Owen G. Roberts", "Aled M. Edwards", "David Uehling", "Rima Al-awar", "Alex N. Bullock", "Jeff A. O’Meara", "Methvin B. Isaac"], "paper_year": 2020, "paper_institution": "Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, MaRS Centre, West Tower, Toronto, Ontario M5G 0A3, Canada", "paper_cited": 2, "doi": "10.1021/acs.jmedchem.0c01199", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-17/acs.jmedchem.0c01199/20200915/images/large/jm0c01199_0017.jpeg", "compound_count": 96, "compound_name": "ldn-214117", "compound_name_drug": "", "compound_smiles": "C1CN(CCN1)c1ccc(c2cncc(c3cc(OC)c(OC)c(OC)c3)c2C)cc1", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 68.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": 1.5, "AUC": "", "solubility": "", "t_half": 3.91, "bioavailability": 96.0}, "clinical_statistics": {}}
articleURL: 383
10.1021/jm070129k
{"compound": "13e", "ic50_mc": "1 2", "selectivity_mc": "1", "compound_drug": "<unk> . in this paragraph , can you find out the result of compound_drug ? [SEP] results and discussion to investigate whether these potential inhibitors 13a−p , 17a , and 17b could inhibit alk5 , a kinase assay was performed using the purified human alk5 kinase domain produced in sf9 insect cells ( table 1 ) . among them , the quinoxalinyl analogue 13e"}


{"id": 38, "paper_title": "Synthesis and Biological Evaluation of 4(5)-(6-Alkylpyridin-2-yl)imidazoles as Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitors", "paper_author": ["Dae-Kee Kim", "Yoojeung Jang", "Ho Soon Lee", "Hyun-Ju Park", "Jakyung Yoo"], "paper_year": 2007, "paper_institution": "College of Pharmacy, Ewha Womans University, 11-1 Daehyun-dong, Seodaemun-gu, Seoul 120-750, Korea, In2Gen Co., Ltd., 608 Daerung Posttower II Building, 182-13 Guro-dong, Guro-gu, Seoul 152-050, Korea, and College of Pharmacy, Sungkyunkwan University, Suwon 440-746, Korea ", "paper_cited": 39, "doi": "10.1021/jm070129k", "paper_journal": "Journal of Medicinal Chemistry", "paper_abstract_image": "https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2007/jmcmar.2007.50.issue-13/jm070129k/production/images/large/jm070129kn00001.jpeg", "compound_count": 63, "compound_name": "13e", "compound_name_drug": "", "compound_smiles": "c1c(nc(cc1)c1c(c2cc3OCOc3cc2)nc([nH]1)NCC1=CC=[C](#N)(C=C1)C)C", "medicinal_chemistry_metrics": {"Ki": "", "Kd": "", "IC50": 12.0, "selectivity": ""}, "pharm_metrics_vitro": {"Ki": "", "Kd": "", "IC50": "", "EC50": "", "selectivity": "", "hERG": "", "solubility": ""}, "pharm_metrics_vivo": {"ED50": "", "AUC": "", "solubility": "", "t_half": "", "bioavailability": ""}, "clinical_statistics": {}}
